<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151184">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01682889</url>
  </required_header>
  <id_info>
    <org_study_id>MUW_Arginin</org_study_id>
    <nct_id>NCT01682889</nct_id>
  </id_info>
  <brief_title>The Effect of High Dose Arginine Infusion on Hemodynamic and Peripheral Microcirculation</brief_title>
  <official_title>The Effect of High Dose Arginine Infusion on Hemodynamic and Peripheral Microcirculation: a Randomized, Controlled Clinical Trial in Patients Receiving Peripheral Vascular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Scientific Fund of the Mayor of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Scientific Fund of the Mayor of Vienna</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to investigate the effect of a 24- hrs L-arginine infusion on
      hemodynamic and on parameters of microcirculation in patients with peripheral arterial
      occlusive disease (PAOD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change from baseline in temperature gradient at 3h post-surgery</measure>
    <time_frame>baseline and 3h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>One temperature probe is attached to the index finger of the lying patients, a second probe at the radial side of the forearm, midway between elbow and the wrist. Temperature gradient is calculated by subtracting the value obtained at the fingertip from the forearm value and expressed in °C.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Laser Doppler blood perfusion imaging at 1h</measure>
    <time_frame>baseline &amp; 1h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Perfusion values are expressed as arbitrary perfusion units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Laser Doppler blood perfusion imaging at 2h</measure>
    <time_frame>baseline &amp; 2h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Perfusion values are expressed as arbitrary perfusion units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Laser Doppler blood perfusion imaging at 3h</measure>
    <time_frame>baseline &amp; 3h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Perfusion values are expressed as arbitrary perfusion units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Laser Doppler blood perfusion imaging at 24h</measure>
    <time_frame>baseline &amp; 24h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Perfusion values are expressed as arbitrary perfusion units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Laser Doppler blood perfusion imaging at 48h</measure>
    <time_frame>baseline &amp; 48h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Perfusion values are expressed as arbitrary perfusion units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in asymmetric dimethylarginine (ADMA) at 3h</measure>
    <time_frame>baseline &amp; 3h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Asymmetric dimethylarginine is measured by ELISA and expressed in µmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in asymmetric dimethylarginine (ADMA) at 24h</measure>
    <time_frame>baseline &amp; 24h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Asymmetric dimethylarginine is measured by ELISA and expressed in µmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in asymmetric dimethylarginine (ADMA) at 48h</measure>
    <time_frame>baseline &amp; 48h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Asymmetric dimethylarginine is measured by ELISA and expressed in µmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma arginine concentration at 3h</measure>
    <time_frame>baseline &amp; 3h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>L-arginine concentration is measured by HPLC and expressed in µmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma arginine concentration at 24h</measure>
    <time_frame>baseline &amp; 24h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>L-arginine concentration is measured by HPLC and expressed in µmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma arginine concentration at 48h</measure>
    <time_frame>baseline &amp; 48h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>L-arginine concentration is measured by HPLC and expressed in µmol/l.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in temperature gradient at 1h</measure>
    <time_frame>baseline &amp; 1h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>One temperature probe is attached to the index finger of the lying patients, a second probe at the radial side of the forearm, midway between elbow and the wrist. Temperature gradient is calculated by subtracting the value obtained at the fingertip from the forearm value and expressed in °C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in temperature gradient at 2h</measure>
    <time_frame>baseline &amp; 2h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>One temperature probe is attached to the index finger of the lying patients, a second probe at the radial side of the forearm, midway between elbow and the wrist. Temperature gradient is calculated by subtracting the value obtained at the fingertip from the forearm value and expressed in °C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in temperature gradient at 24h</measure>
    <time_frame>baseline &amp; 24h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>One temperature probe is attached to the index finger of the lying patients, a second probe at the radial side of the forearm, midway between elbow and the wrist. Temperature gradient is calculated by subtracting the value obtained at the fingertip from the forearm value and expressed in °C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in temperature gradient at 48h</measure>
    <time_frame>baseline &amp; 48h post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>One temperature probe is attached to the index finger of the lying patients, a second probe at the radial side of the forearm, midway between elbow and the wrist. Temperature gradient is calculated by subtracting the value obtained at the fingertip from the forearm value and expressed in °C.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Peripheral Arterial Occlusive Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9% intravenously for 24 hours after induction of anaesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arginine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours after induction of anaesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arginine</intervention_name>
    <description>L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours</description>
    <arm_group_label>Arginine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>NaCl 0.9% intravenously for 24h</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female or male patients receiving peripheral bypass surgery

          -  age between 55 and 75 years

        Exclusion Criteria:

          -  metabolic acidosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jörg Michael Hiesmayr, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 6, 2012</lastchanged_date>
  <firstreceived_date>September 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Ass.-Prof. DI Dr. Barbara Wessner</investigator_full_name>
    <investigator_title>Ass.-Prof. DI Dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
